Get started
Author

Mayukh Das

Observed names: Das, Mayukh, M Das, M. Das
Observed institutions: Eli Lilly (United States), Hadassah Medical Center, Tata Memorial Hospital, Eli Lilly (United Kingdom), The Christie Hospital, The Christie NHS Foundation Trust, AstraZeneca (United States), Arcus Biosciences (United States)
ORCID: 0000-0002-7384-551X
Observed ORCID: 0000-0002-7384-551X
OpenAlex ID: A5019353672
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
2016 · D.A. Fennell, Y. Summers, et al. · Cancer Treatment Reviews · 390
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
2019 · Charles S Fuchs, Kohei Shitara, et al. · The Lancet Oncology · 300
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
2017 · D. Arnold, C.S. Fuchs, et al. · Annals of Oncology · 125
PDF
First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer
2021 · Mark D. Pegram, Erika P. Hamilton, et al. · Molecular Cancer Therapeutics · 111
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
2022 · Emerson A. Lim, Johanna C. Bendell, et al. · Clinical Cancer Research · 96
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
2024 · Sandip P Patel, Teresa Alonso-Gordoa, et al. · Journal for ImmunoTherapy of Cancer · 70
PDF
Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non–Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial
2013 · Marianne C. Nicolson, Dean A. Fennell, et al. · Journal of Thoracic Oncology · 59
PDF
Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non–Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study
2014 · Ronald Natale, Fiona Blackhall, et al. · Journal of Thoracic Oncology · 50
Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia
2003 · M Das, T K Saikia, et al. · Bone Marrow Transplantation · 41
RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma.
2018 · Charles S. Fuchs, Kohei Shitara, et al. · Journal of Clinical Oncology · 28
Mycobacterial Pulmonary Infection Post Allogeneic Bone Marrow Transplantation
2001 · Unmesh Mohite, Mayukh Das, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 16
A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).
2016 · Charles S. Fuchs, Josep Tabernero, et al. · Journal of Clinical Oncology · 13
Association between Gene Expression Profiles and Clinical Outcome of Pemetrexed-Based Treatment in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Exploratory Results from a Phase II Study
2014 · Dean A. Fennell, Scott P. Myrand, et al. · PLoS ONE · 11
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors
2024 · Ben Tran, Mark Voskoboynik, et al. · Immunotherapy · 10
Donor cell leukemia following unrelated donor bone marrow transplantation for primary granulocytic sarcoma of the small intestine
2010 · Daniel H. Wiseman, Mayukh Das, et al. · American Journal of Hematology · 10
PDF
First-line durvalumab + monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC).
2020 · Zev A. Wainberg, Jennifer Robinson Diamond, et al. · Journal of Clinical Oncology · 9
Ramucirumab as First-Line Therapy in Combination with Cisplatin and Fluoropyrimidine in Patients with Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma (RAINFALL): A Global, Randomised, Double-Blinded, Placebo-Controlled, Phase 3 Trial
2018 · Charles Fuchs, Kohei Shitara, et al. · SSRN Electronic Journal · 9
Abstract CT126: A phase 2 trial of first-line AZD0171 + durvalumab and chemotherapy (CT) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) and CD8+ T cell infiltration
2022 · Grainne O'Kane, Teresa Macarulla, et al. · Cancer Research · 7
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
2017 · D. Arnold, C.S. Fuchs, et al. · Annals of Oncology · 7
PDF
Population Pharmacokinetics of Monalizumab in Patients With Advanced Solid Tumors
2023 · Michael Hwang, Chunling Fan, et al. · The Journal of Clinical Pharmacology · 6
A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophogeal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).
2015 · Charles S. Fuchs, Josep Tabernero, et al. · Journal of Clinical Oncology · 6
518 Phase 1B trial of monalizumab (NKG2A inhibitor) plus durvalumab: safety and efficacy in patients with metastatic ovarian, cervical, and microsatellite-stable endometrial cancers
2020 · Susana Banerjee, Ana Oaknin, et al. · International Journal of Gynecological Cancer · 5
PDF
Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I study
2024 · A. Algazi, K.P. Papadopoulos, et al. · ESMO Open · 4
PDF
A randomized open-label phase II study evaluating antitumor activity of the survivin antisense oligonucleotide LY2181308 (LY) in combination with docetaxel (DO) for second-line treatment of patients with non-small cell lung cancer (NSCLC) using change in tumor size (CTS).
2013 · Denis Charles Talbot, Fiona Helen Blackhall, et al. · Journal of Clinical Oncology · 4
Correlation between thymidylate synthetase (TS) expression and progression-free survival (PFS) in patients receiving pemetrexed (pem) for advanced NSCLC: A prospective study.
2012 · Marianne Nicolson, Keith M Kerr, et al. · Journal of Clinical Oncology · 4
Works count: 61
Citation count: 1,403
H-index: 12
I10-index: 15
Year
Topic
Type